New York State Common Retirement Fund Sells 8,406 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

New York State Common Retirement Fund lessened its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 381,413 shares of the company’s stock after selling 8,406 shares during the period. New York State Common Retirement Fund’s holdings in Elanco Animal Health were worth $5,683,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. bought a new stake in Elanco Animal Health in the 3rd quarter valued at $37,912,000. Ancora Advisors LLC acquired a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $37,189,000. Black Creek Investment Management Inc. increased its stake in Elanco Animal Health by 12.8% in the third quarter. Black Creek Investment Management Inc. now owns 15,523,457 shares of the company’s stock valued at $174,484,000 after acquiring an additional 1,759,556 shares during the period. Barclays PLC raised its position in Elanco Animal Health by 334.7% in the third quarter. Barclays PLC now owns 1,529,134 shares of the company’s stock worth $17,188,000 after purchasing an additional 1,177,403 shares in the last quarter. Finally, Landscape Capital Management L.L.C. bought a new position in Elanco Animal Health during the third quarter worth about $10,084,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Elanco Animal Health

In other news, Director R David Hoover bought 20,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was bought at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the transaction, the director now directly owns 185,000 shares in the company, valued at approximately $2,985,900. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.57% of the company’s stock.

Analyst Ratings Changes

ELAN has been the topic of several analyst reports. Morgan Stanley upped their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. The Goldman Sachs Group upped their price target on Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research report on Tuesday, February 27th. TheStreet raised Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. Finally, Barclays upped their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $13.53 on Friday. Elanco Animal Health Incorporated has a 12-month low of $7.88 and a 12-month high of $16.88. The stock has a 50-day simple moving average of $15.08 and a 200 day simple moving average of $13.92. The company has a quick ratio of 1.35, a current ratio of 2.75 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $6.69 billion, a price-to-earnings ratio of -5.41, a P/E/G ratio of 1.42 and a beta of 1.34.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Monday, February 26th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. Elanco Animal Health’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.19 earnings per share. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.